Dr. Phillip Alan Tenzel, MD

Dr. Tenzel practices at University of Texas Southwestern Medical Center at Dallas in Fort Worth, Texas.

Dr. Tenzel's NPI, 1033536396, was assigned on March 25, 2014. Dr. Tenzel graduated from University of Miami, Miller School of Medicine in 2014. Dr. Tenzel holds Texas license S0810.

Dr. Tenzel's primary practice is University of Texas Southwestern Medical Center at Dallas, at 600 S Main St, Fort Worth, TX 76104 in Tarrant County. The practice phone is (817) 882-2400.

Dr. Tenzel's primary practice is University of Texas Southwestern Medical Center at Dallas in Fort Worth, Texas. Dr. Tenzel is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Tenzel to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tenzel practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Tenzel's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Tenzel is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Tenzel's licenses on file in 3 states: Texas, Florida and New York.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and vision problems among the conditions Dr. Tenzel treats.

CMS data shows 7,682 Medicare services from Dr. Tenzel across 14 procedure codes in 2024, for 321 Medicare patients. Medicare paid $98,725 for them.

CMS counts 321 Medicare patients who saw Dr. Tenzel in 2024. The largest group is 65 to 74, with 146 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.24, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tenzel's median patient age at 69, with 57% women.

In 2024, Dr. Tenzel wrote 338 Medicare Part D claims for 180 patients. 88% of them were for generic drugs. CMS names the drug for 280 of them, across 7 drugs with 11 or more claims each, at $4,618 in total drug cost. In 2023, CMS named 187 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Tenzel for performance year 2024, reported as part of a group. Dr. Tenzel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 15 procedures of melanoma (skin cancer) excision by Dr. Tenzel, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 13 papers to Dr. Tenzel, published from 2016 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Blepharoplasty, Blepharoptosis and Oculomotor Muscles. Dr. Tenzel has published most often in Orbit. Dr. Tenzel's most frequent co-authors are Ronald Mancini, MD, Harsha Reddy, MD and Jorge S. Andrade Romo, MD.

CMS Open Payments shows 16 general payments to Dr. Tenzel from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $393.

Dr. Tenzel graduated from University of Miami, Miller School of Medicine in 2014.

Dr. Tenzel is in network with 23 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 14. Check the plan with the practice before a visit.